A survey on the use of Rh immune globulin during a nationwide shortage
Transfusion · 2025
DOI: 10.1111/trf.18465 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, 2025. Verfasst von Kerry O'Brien und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Rho(D) Immune Globulin, Rh Isoimmunization. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background
Rh immune globulin (RhIG) is used to prevent D alloimmunization and reduce the risk of hemolytic disease of the fetus and newborn (HDFN). Its use has been expanded to include immunoprophylaxis after D‐incompatible transfusions. In the United States, a protracted RhIG shortage began in 2023. The AABB (Association for the Advancement of Blood & Biotherapies) Clinical Hemotherapy Subsection created a survey to assess RhIG usage patterns during this shortage.
Methods
A survey was developed and electronically distributed to AABB‐accredited institutions. The number of responses was tallied. Frequencies were calculated, and free text comments were categorized.
Results
A total of 112 responses (13.7%) were received from all regions of the United States. While 6.2% (6/97) of respondents noticed increased RhIG usage, 70.0% (56/80) experienced a shortage of RhIG. The most common indication reported for RhIG use was D‐negative pregnant patients carrying a D‐unknown or D‐positive fetus/neonate. Some respondents also permitted RhIG use in D‐negative adult males and females outside of childbearing age following D‐incompatible transfusion. The most common institutional responses to the shortage were to: formally monitor RhIG inventory ( n = 37), add ( n = 34)/switch ( n = 24) manufacturers, and redistribute RhIG between facilities ( n = 22). Few respondents ( n = 7) limited or discontinued RhIG use in non‐obstetric patients.
Conclusions
While the majority of survey respondents were affected by the RhIG shortage, transfusion services still allowed RhIG to be issued outside of obstetric care. Given that RhIG is a limited resource and its intended goal is to reduce anti‐D HDFN, more effective management of RhIG utilization is needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Department of Obstetrics & Gynecology, Yale University Medical Center, New Haven, Connecticut, USA.
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.
- Department of Pathology, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
- Department of Pathology, University of California San Diego, San Diego, California, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Kerry O'Brien, Melissa George, Laura Stephens, Wen Lu
Zitieren
APA
O'Brien, K., Abels, E., Bakhtary, S., George, M., Stephens, L., & Lu, W. (2025). A survey on the use of Rh immune globulin during a nationwide shortage. Transfusion. https://doi.org/10.1111/trf.18465
Vancouver
O'Brien K, Abels E, Bakhtary S, George M, Stephens L, Lu W. A survey on the use of Rh immune globulin during a nationwide shortage. Transfusion. 2025. doi:10.1111/trf.18465
BibTeX
@article{OBrien2025,
author = {O'Brien, Kerry and Abels, Elizabeth and Bakhtary, Sara and George, Melissa and Stephens, Laura and Lu, Wen},
title = {A survey on the use of Rh immune globulin during a nationwide shortage},
journal = {Transfusion},
year = {2025},
doi = {10.1111/trf.18465}
}
EUVIMED